Compare NREF & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | FULC |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.5M | 285.4M |
| IPO Year | N/A | 2019 |
| Metric | NREF | FULC |
|---|---|---|
| Price | $17.13 | $3.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $14.00 | ★ $16.38 |
| AVG Volume (30 Days) | 44.5K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-27-2026 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.36 | $2.83 |
| 52 Week High | $18.43 | $15.74 |
| Indicator | NREF | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 54.15 |
| Support Level | $16.39 | $3.44 |
| Resistance Level | $17.22 | $3.96 |
| Average True Range (ATR) | 0.58 | 0.14 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 36.29 | 89.77 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.